{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:20Z","timestamp":1792787300243,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cuban Ministry of Health","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Center of Molecular Immunology","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/01gh7yb82","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD6 is a promising target in cancer immunotherapy, with preclinical evidence supporting its role in modulating immune responses. This warrants further investigation into current CD6-targeting treatments, which could lead to new anti-tumor therapies. However, the clinical effects of targeting CD6 in solid tumors remain unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This proof-of-concept study is the first in-human evaluation of the safety and early effectiveness of anti-CD6 monoclonal antibody itolizumab in patients with advanced, highly heterogeneous solid tumors. Treatment had two phases: induction and maintenance. In induction, group A received 100 mg weekly for nine doses; group B received 200 mg biweekly for five doses. After completing induction, patients moved to maintenance 21 days later, receiving 100 mg every 21 days for up to six doses. The primary endpoint was safety; secondary objectives included disease control, survival, and exploratory molecular mechanisms and blood biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Itolizumab demonstrated a favorable safety profile, with no safety-related treatment discontinuations, no related serious adverse events, and no unexpected toxicities. In this heavily treated, non-biomarker-selected population, disease control was achieved in 25% in group A and 20% in group B, and the 1-year survival rate was 26% in group A and 15% in group B. Mechanistically, ex vivo analysis demonstrated that itolizumab downregulates CD6, increasing soluble CD6 levels and promoting a cytotoxic phenotype on CD8 and NK cells. Additionally, patient-derived peripheral blood mononuclear cells demonstrated boosted in vitro killing capacity specifically against CD318+ cancer cells. The antibody also modulates PD-1 expression in peripheral lymphocytes, promoting NK cell activity while maintaining inhibitory signals on CD8+ T cells and decreasing T helper overactivation. These findings support the dual role of itolizumab, enhancing anti-tumor responses while preventing autoimmune-like effects by reducing off-target inflammation and avoiding immune-related adverse effects associated with immune checkpoint therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, these findings support further development of itolizumab as a rational immunomodulatory strategy with a favorable safety profile for advanced solid tumors, particularly in CD318-expressing tumors and as part of rational combination regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>RPCEC00000444.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-016182","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:27Z","timestamp":1791385227000},"page":"e016182","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CD6 in solid tumors: safety, early efficacy, and mechanistic insights from a proof-of-concept trial of itolizumab"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-3018","authenticated-orcid":false,"given":"Cynthia","family":"Gonz\u00e1lez Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raiza","family":"Ruiz-Lorente","sequence":"additional","affiliation":[{"name":"Oncology Department, \u201cRam\u00f3n Gonz\u00e1lez Coro\u201d Obstetrics and Gynecology Teaching Hospital, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Blanco-Pita","sequence":"additional","affiliation":[{"name":"Oncology Department, Comandante Manuel Fajardo University Hospital, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noralys","family":"Lara-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Oncology Department, \u201cMiguel Enr\u00edquez\u201d Hospital, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Elena","family":"Salom\u00f3n","sequence":"additional","affiliation":[{"name":"Oncology Department, \u201cJoaqu\u00edn Albarr\u00e1n\u201d Clinic-Surgical Teaching Hospital, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Alv\u00e1rez Lobaina","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8397-7935","authenticated-orcid":false,"given":"Jenysbel de la Caridad","family":"Hernandez Reyes","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9164-0238","authenticated-orcid":false,"given":"Patricia Lorenzo-Luaces","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-5940","authenticated-orcid":false,"given":"Mayel\u00edn","family":"Troche-Concepci\u00f3n","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-3119","authenticated-orcid":false,"given":"Loipa","family":"Medel Perez","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanela","family":"Santiesteban-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-3975","authenticated-orcid":false,"given":"Daymys","family":"Estevez-Iglesias","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arasay","family":"Montes-D\u2019Santis","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-6207","authenticated-orcid":false,"given":"Aym\u00e9","family":"Fern\u00e1ndez-Calienes Vald\u00e9s","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-7292","authenticated-orcid":false,"given":"Tania","family":"Crombet Ramos","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9058-3224","authenticated-orcid":false,"given":"Mayra","family":"Ramos Suzarte","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-0988","authenticated-orcid":false,"given":"Mayrel","family":"Labrada Mon","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology, Havana, Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100708002115000_14.10.e016182.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26072923","article-title":"Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies","volume":"26","author":"Giri","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026100708002115000_14.10.e016182.2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12531"},{"key":"2026100708002115000_14.10.e016182.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298571","article-title":"The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy","volume":"14","author":"Mej\u00eda-Guarnizo","year":"2023","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"2026100708002115000_14.10.e016182.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102614"},{"key":"2026100708002115000_14.10.e016182.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1528478","article-title":"Ligands of CD6: roles in the pathogenesis and treatment of cancer","volume":"15","author":"Gurrea-Rubio","year":"2024","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01130-4"},{"key":"2026100708002115000_14.10.e016182.8","doi-asserted-by":"crossref","DOI":"10.3390\/cells14040272","article-title":"CD6 in Human Disease","volume":"14","author":"Gurrea-Rubio","year":"2025","journal-title":"Cells"},{"key":"2026100708002115000_14.10.e016182.9","doi-asserted-by":"publisher","DOI":"10.1159\/000322720"},{"key":"2026100708002115000_14.10.e016182.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.07.005"},{"key":"2026100708002115000_14.10.e016182.11","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201011","article-title":"The T cell CD6 receptor operates a multitask signalosome with opposite functions in T cell activation","volume":"218","author":"Mori","year":"2021","journal-title":"J Exp Med"},{"key":"2026100708002115000_14.10.e016182.12","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150531152439"},{"key":"2026100708002115000_14.10.e016182.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00769","article-title":"Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses","volume":"8","author":"Carrasco","year":"2017","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-022-00998-x","article-title":"CD6-mediated inhibition of T cell activation via modulation of Ras","volume":"20","author":"Henriques","year":"2022","journal-title":"Cell Commun Signal"},{"key":"2026100708002115000_14.10.e016182.15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4049\/jimmunol.208.Supp.105.34","article-title":"The CD6-ALCAM pathway selectively modulates pathogenic T cell migration","volume":"208","author":"Marrocco","year":"2022","journal-title":"J Immunol"},{"key":"2026100708002115000_14.10.e016182.16","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/130646","article-title":"Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases","volume":"2010","author":"Alonso-Ramirez","year":"2010","journal-title":"Arthritis"},{"key":"2026100708002115000_14.10.e016182.17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1172\/jci.insight.172914","article-title":"A CD6-targeted antibody-drug conjugate as a potential therapy for T cell\u2013mediated disorders","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI Insight"},{"key":"2026100708002115000_14.10.e016182.18","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/j.clml.2024.06.013","article-title":"Expression of CD6 in Aggressive NK\/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group Study","volume":"24","author":"Zhao","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026100708002115000_14.10.e016182.19","doi-asserted-by":"crossref","first-page":"17510","DOI":"10.3390\/ijms242417510","article-title":"CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies","volume":"24","author":"Arag\u00f3n-Serrano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026100708002115000_14.10.e016182.20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1026521"},{"key":"2026100708002115000_14.10.e016182.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000172","article-title":"Multifaceted effects of soluble human CD6 in experimental cancer models","volume":"8","author":"Sim\u00f5es","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026100708002115000_14.10.e016182.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101575","article-title":"CD166-specific CAR-T cells potently target colorectal cancer cells","volume":"27","author":"He","year":"2023","journal-title":"Transl Oncol"},{"key":"2026100708002115000_14.10.e016182.23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145662","article-title":"CD6 is a target for cancer immunotherapy","volume":"6","author":"Ruth","year":"2021","journal-title":"JCI Insight"},{"key":"2026100708002115000_14.10.e016182.24","doi-asserted-by":"crossref","unstructured":"Gurrea-Rubio M , Wu Q , Amin MA , et al . Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells. Res Sq 2023. doi:10.21203\/rs.3.rs-3405677\/v1","DOI":"10.21203\/rs.3.rs-3405677\/v1"},{"key":"2026100708002115000_14.10.e016182.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180088","article-title":"T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab","volume":"12","author":"Bughani","year":"2017","journal-title":"PLoS One"},{"key":"2026100708002115000_14.10.e016182.26","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666160201114308"},{"key":"2026100708002115000_14.10.e016182.27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14712598.2020.1798399","article-title":"Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications","volume":"20","author":"Loganathan","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026100708002115000_14.10.e016182.28","first-page":"257","article-title":"Itolizumab humanized monoclonal antibody (anti-cd6) in patients with cd6+ lymphoproliferative disorders. Preliminary experience","volume":"30","author":"Izquierdo","year":"2014","journal-title":"Rev Cubana Hematol Inmunol Hemoter"},{"key":"2026100708002115000_14.10.e016182.29","doi-asserted-by":"crossref","first-page":"1585597","DOI":"10.3389\/fimmu.2025.1585597","article-title":"Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines","volume":"16","author":"Gonz\u00e1lez Mu\u00f1oz","year":"2025","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.30","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/jimmun\/vkaf208","article-title":"Enhanced affinity for the IL-2 receptor \u03b2 subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment","volume":"214","author":"Relova-Hern\u00e1ndez","year":"2025","journal-title":"J Immunol"},{"key":"2026100708002115000_14.10.e016182.31","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148805","article-title":"Antigenic Modulation of CD6 By Itolizumab Is a New Mechanism for Effector T Cell Inhibition","volume":"138","author":"Chu","year":"2021","journal-title":"Blood"},{"key":"2026100708002115000_14.10.e016182.32","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5306\/wjco.v15.i8.1002","article-title":"Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors","volume":"15","author":"Guo","year":"2024","journal-title":"World J Clin Oncol"},{"key":"2026100708002115000_14.10.e016182.33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med"},{"key":"2026100708002115000_14.10.e016182.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2026100708002115000_14.10.e016182.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026100708002115000_14.10.e016182.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02994","article-title":"CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation","volume":"9","author":"Gon\u00e7alves","year":"2018","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.38","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-07650-5","article-title":"Targeting NKG2D\/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications","volume":"24","author":"Wei","year":"2026","journal-title":"J Transl Med"},{"key":"2026100708002115000_14.10.e016182.39","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2026.2622794","article-title":"Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human disease","volume":"22","author":"Glover","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"2026100708002115000_14.10.e016182.40","doi-asserted-by":"crossref","first-page":"960852","DOI":"10.3389\/fimmu.2022.960852","article-title":"Implications of NKG2A in immunity and immune-mediated diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000586","article-title":"Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer","volume":"8","author":"Hurkmans","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026100708002115000_14.10.e016182.42","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0641"},{"key":"2026100708002115000_14.10.e016182.43","doi-asserted-by":"crossref","first-page":"103228","DOI":"10.1016\/j.jaut.2024.103228","article-title":"The CD318\/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation","volume":"146","author":"Do","year":"2024","journal-title":"J Autoimmun"},{"key":"2026100708002115000_14.10.e016182.44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009416","article-title":"Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK\/STAT signaling pathway","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026100708002115000_14.10.e016182.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3881"},{"key":"2026100708002115000_14.10.e016182.46","doi-asserted-by":"crossref","first-page":"1571590","DOI":"10.3389\/fimmu.2025.1571590","article-title":"The OT-II model reveals dual in vitro and in vivo immunomodulatory properties of CD6 in T cell activation","volume":"16","author":"Leyton-Pereira","year":"2025","journal-title":"Front Immunol"},{"key":"2026100708002115000_14.10.e016182.47","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1007\/s00262-023-03539-8","article-title":"Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma","volume":"72","author":"Tachiki","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026100708002115000_14.10.e016182.48","doi-asserted-by":"crossref","first-page":"906251","DOI":"10.3389\/fonc.2022.906251","article-title":"Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"2026100708002115000_14.10.e016182.49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03441-3"},{"key":"2026100708002115000_14.10.e016182.50","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-025-01093-3","article-title":"Single-cell RNA-sequencing of BCG na\u00efve and recurrent non-muscle invasive bladder cancer reveals a CD6\/ALCAM-mediated immune-suppressive pathway","volume":"9","author":"Juric","year":"2025","journal-title":"NPJ Precis Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-016182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:32Z","timestamp":1791385232000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-016182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,7]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-016182"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-016182","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}